Abbott (NYSE:ABT) today announce real-world data demonstrating reductions in hospitalizations associated with the FreeStyle Libre system. The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily […]
Abbott
4 major cardiology trends you need to know from TCT 2022
Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive. The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations. Medtronic, Abbott, Edwards and Boston Scientific represent a few of the […]
Edwards TEER therapy proves safe and effective in head-to-head trial with Abbott MitraClip
Edwards Lifesciences (NYSE:EW) announced data confirming its transcatheter edge-to-edge repair (TEER) as safe and effective. CLASP IID compared Edwards’ Pascal system and Abbott’s MitraClip system. The study determined that the two contemporary TEER therapies are safe and effective in patients with degenerative mitral regurgitation (DMR). Results from the trial were presented at the 34th Transcatheter […]
Abbott says study backs Amplatzer Amulet against Boston Scientific’s Watchman
Abbott (NYSE:ABT) today presented data supporting the use of its Amplatzer Amulet against Boston Scientific’s (NYSE:BSX) competing device. Device-related factors and all-cause death represented categories favoring Amplatzer Amulet against Watchman, according to a news release. Abbott designed its Amplatzer Amulet left atrial appendage (LAA) occluder with dual-seal technology. It features a lobe or piece to fill the […]
Data reinforces value of Abbott MitraClip for treating MR
Abbott (NYSE:ABT) today announced post-approval study results supporting its MitraClip G4 system for treating mitral regurgitation (MR). The company presented data from the EXPAND G4 study at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in Boston. EXPAND G4 evaluated MitraClip G4, the company’s transcatheter edge-to-edge repair (TEER) device […]
FDA warns of clip lock issue on some Abbott MitraClip heart valves
The FDA alerted healthcare providers about potential malfunctions with the Abbott (NYSE:ABT) MitraClip clip delivery systems. On Sept. 8, Abbott issued an urgent medical device correction. It informed providers of an increased rate of reports of clip lock malfunctions. Users observed malfunctions both before and after clip deployment. The FDA notice said the events appear […]
What are the largest medical device companies?
Medtronic, Johnson & Johnson MedTech and Siemens Healthineers top the Big 100 list of largest medical device companies by revenue. The 2022 edition of MassDevice and Medical Design & Outsourcing‘s Big 100 report also holds surprises. Big conglomerates are spinning out medtech businesses as stand-alone companies, and that means changes to the list of the […]
Data supports Abbott Amplatzer Piccolo for fixing holes in newborn hearts without surgery
Abbott (NYSE:ABT) announced today that three-year data demonstrated the positive impact of its Amplatzer Piccolo Occluder on babies. The device treats newborns — some weighing as little as two pounds — with a hole in the heart. The condition, known as patent ductus arteriosus (PDA), is potentially life-threatening. PDA is present in approximately one of […]
Abbott launches Amplatzer Talisman occlusion system in Europe
Abbott (NYSE:ABT) announced today that it launched its Amplatzer Talisman patent foramen ovale (PFO) occlusion system in Europe. PFO is a hole in the heart that doesn’t close following birth. The company designed the Amplatzer Talisman to treat people with PFO who experienced a stroke and are at risk of having another. Occlusion with the […]
Study says Abbott’s HeartMate3 heart pump extends survival by 5 years
Abbott (NYSE:ABT) announced today that data demonstrates extended survival for advanced heart failure patients using HeartMate 3. Data from the Momentum 3 trial — the world’s largest randomized clinical trial to assess long-term outcomes in people receiving a left ventricular assist device (also known as an LVAD or heart pump) to treat advanced heart failure […]
FDA approves Abbott’s next-gen spinal cord stimulation therapy
Abbott (NYSE:ABT) announced today that the FDA approved its new Proclaim Plus spinal cord stimulation (SCS) system with FlexBurst360. The FlexBurst360 therapy is the next generation of Abbott’s proprietary BurstDR stimulation. Abbott designed it to provide pain coverage across up to six areas of the trunk and/or limbs. It has programming that adjusts as a […]
